The hottest thing in cancer drug development is a takeover target again — here’s what you need to know about it (JUNO, CELG)
|01/17/2018||Posted by BusinessMediaguide.Com under General World News||
- Biotech giant Celgene is in talks to acquire Juno Therapeutics, The Wall Street Journal reported on Tuesday.
- If the deal goes through, it’d be the second deal in the past few months for companies working on treatments that use the body’s immune cells to fight cancer, following Gilead’s acquisition of Kite Pharma.
- These highly personalized treatments, called CAR T-cell therapy, are at the beginning of what some are calling “a big new field of medicine.”
A new form of cancer treatment that harnesses the body’s immune cells to treat cancer is back in the headlines.